A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection

Trial Profile

A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs RBX 2660 (Primary)
  • Indications Clostridium infections; Diarrhoea
  • Focus Therapeutic Use
  • Acronyms PUNCHCD2
  • Sponsors Rebiotix
  • Most Recent Events

    • 07 Jun 2017 According to a Rebiotix media release, results from this trial were presented at the American Society for Microbiology's ASM Microbe 2017.
    • 07 Jun 2017 Primary endpoint has been met. (Efficacy of Active Treatment Compared to Placebo at Measured at 8 weeks Post-treatment)
    • 09 May 2017 Results assessing correlations between longitudinal patient microbiome data and efficacy of RBX2660, presented at the Digestive Disease Week 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top